Integrative neurochemistry and neurobiology of social recognition and behavior analyzed with respect to CD38-dependent brain oxytocin secretion

Current Topics in Medicinal Chemistry

Volumn 13, Issue 23, 2013, Pages 2965-2977

  Salmina, Alla B ^a,b   Lopatina, Olga ^b   Kuvacheva, Natalia V ^b   Higashida, Haruhiro ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b KRASNOYARSK STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

CD38; Oxytocin; Social behavior

Indexed keywords

4 AMINOBUTYRIC ACID; ADENOSINE TRIPHOSPHATE; ANGIOTENSIN II; ARGIPRESSIN; CD38 ANTIGEN; CYCLIC ADENOSINE DIPHOSPHATE RIBOSE; DOPAMINE; ESTRADIOL; ESTROGEN; GAP JUNCTION PROTEIN; GLUTAMIC ACID; INTERLEUKIN 1BETA; NEUROPEPTIDE; NEUROSTEROID; NEUROTRANSMITTER; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE NUCLEOSIDASE; NITRIC OXIDE; NORADRENALIN; OXYTOCIN; OXYTOCIN RECEPTOR; PROSTAGLANDIN; PURINERGIC P2X7 RECEPTOR; RETINOIC ACID; RYANODINE RECEPTOR 2; RYANODINE RECEPTOR 3; THYROID HORMONE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

AMYGDALOID NUCLEUS; ANTIGENIC MODULATION; ANXIETY; APOPTOSIS; AUTISM; BRAIN DEVELOPMENT; CELL ACTIVITY; FEAR; GENE EXPRESSION; HOMEOSTASIS; HUMAN; IMMUNOREACTIVITY; MATERNAL CARE; NERVOUS SYSTEM INFLAMMATION; NEUROBIOLOGY; NEUROCHEMISTRY; NEUROSECRETION; NONHUMAN; OXYTOCIN RELEASE; PROTEIN EXPRESSION; RECOGNITION; REVIEW; SIGNAL TRANSDUCTION; SOCIAL BEHAVIOR; STRESS; UPREGULATION;

ANIMALS; ANTIGENS, CD38; BRAIN; GLYCOSIDE HYDROLASES; HUMANS; NAD; OXYTOCIN; RECOGNITION (PSYCHOLOGY); SOCIAL BEHAVIOR;

EID: 84889030909     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/15680266113136660211     Document Type: Review

References (182)

1. Nikiforov, A.; Dölle, C.; Niere, M.; Ziegler, M. Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation. J. Biol. Chem., 2011, 286, 21767-21778.
2. + and NADH in brain functions, brain diseases and brain aging. Front. Biosci., 2007, 12, 1863-1888.
3. +) in the rat brain. Eur. J. Neurosci., 2012, 35, 423-435.
4. Higashida, H.; Salmina, A. B.; Olovyannikova, R. Y.; Hashii, M.; Yokoyama, S.; Koizumi, K.; Jin, D.; Liu, H. X.; Lopatina, O.; Amina, S.; Islam, M. S.; Huang, J. J.; Noda, M. Cyclic ADP-ribose as a universal calcium signal molecule in the nervous system. Neurochem. Int., 2007, 51, 192-199.
5. Salmina, A. B.; Lopatina, O.; Ekimova, MV.; Mikhutkina, S. V.; Higashida, H. CD38/cyclic ADP-ribose system: a new player for oxytocin secretion and regulation of social behaviour. J. Neuroendocrinol., 2010, 22, 380-392.
6. Salmina, A. B. Neuron-glia interactions as therapeutic targets in neurodegeneration. J. Alzheimers Dis., 2009, 16, 485-502.
7. +-converting enzymes in neuronal and glial cells: CD38 as a novel target for neuroprotection. Vestn. Ross. Akad. Med. Nauk., 2012, 10, 29-37.
8. 2+ pathway promotes cell proliferation and delays nerve growth factor-induced differentiation in PC12 cells. J. Biol. Chem., 2009, 284, 29335-29342.
9. Graeff, R.; Liu, Q.; Kriksunov, I. A.; Kotaka, M.; Oppenheimer, N.; Hao, Q.; Lee, H. C. Mechanism of cyclizing NAD to cyclic ADPribose by ADP-ribosyl cyclase and CD38. J. Biol. Chem., 2009, 284, 27629-27636.
10. Howard, M.; Grimaldi, J. C., Bazan, J. F., Lund, F. E., Santos-Argumedo, L., Parkhouse, R. M., Walseth, T. F., Lee H. C. Forma tion and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science, 1993, 262, 1056-1059.
11. Kim, H.; Jacobson, E. L.; Jacobson, M. K. Synthesis and degradation of cyclic ADP-ribose by NAD. glycohydrolases. Science, 1993, 261, 1330-1333.
12. Lee, H. C.; Zocchi, E.; Guida, L.; Franco, L.; Benatti, U.; De Flora, A. Production and hydrolysis of cyclic ADP-ribose at the outer surface of human erythrocytes. Biochem. Biophys. Res. Commun., 1993, 191, 639-645.
13. Takasawa, S.; Tohgo, A.; Noguchi, N., Koguma, T., Nata, K., Sugimoto, T., Yonekura, H., Okamoto, H. Synthesis and hydrolysis of cyclic ADP-ribose by human leukocyte antigen CD38 and inhibition of the hydrolysis by ATP. J. Biol. Chem., 1993, 268, 26052-26054.
14. 2+ signaling by translocation of the Ca2+ messenger synthesizing enzyme ADP-ribosyl cyclase during neuronal depolarization. J. Biol. Chem., 2008, 283, 27859-27870.
15. Akimoto, N.; Kamiyama, Y.; Yamafuji, M.; Fujita, K.; Seike, T.; Kido, M. A.; Yokoyama, S.; Higashida, H.; Noda, M. Immunohistochemistry of CD38 in different cell types in the hypothalamus and pituitary of male mice. Messenger, 2013, 1, 54-61.
16. Ceni, C.; Pochon, N.; Villaz, M.; Muller-Steffner, H.; Schuber, F.; Baratier, J.; De Waard, M.; Ronjat, M.; Moutin, M. J. The CD38-independent ADP-ribosyl cyclase from mouse brain synaptosomes: a comparative study of neonate and adult brain. Biochem. J., 2006, 395, 417-426.
17. Malavasi, F.; Deaglio, S.; Funaro, A.; Ferrero, E.; Horenstein, A. L.; Ortolan, E.; Vaisitti, T.; Aydin, S. Evolution and function of the ADP cibosyl cyclase/CD38 gene family in physiology and pathology. Physiol. Rev., 2008, 88, 841-886.
18. + glycohydrolase-catalysed reactions: implication for CD38 signaling. Biochem. J., 2001, 358, 399-406.
19. Zhao, Y. J.; Lam, C. M.; Lee, H. C. The membrane-bound enzyme CD38 exists in two opposing orientations. Sci. Signal., 2012, 5, ra67.
20. + sensor. FASEB J., 2002, 16, 302-314.
21. Yamada, M.; Mizuguchi, M.; Otsuka, N.; Ikeda, K.; Takahashi, H. Ultrastructural localization of CD38 immunoreactivity in rat brain. Brain Res., 1997, 756, 52-60.
22. +-dependent mechanisms of disturbances of viability of brain cells during the acute period of hypoxic-ischemic perinatal injury. J. Neurochem., 2008, 2, 215-221.
23. Higashida, H.; Zhang, J. S.; Mochida, S.; Chen, X. L.; Shin, Y.; Noda, M.; Hossain, K. Z.; Hoshi, N.; Hashii, M.; Shigemoto, R.; Nakanishi, S.; Fukuda, Y.; Yokoyama, S. Subtype-specific coupling with ADP-ribosyl cyclase of metabotropic glutamate receptors in retina, cervical superior ganglion and NG108-15 cells. J. Neurochem., 2003, 85, 1148-1158.
24. Noda, M.; Yasuda, S.; Okada, M.; Higashida, H.; Shimada, A.; Iwata, N.; Ozaki, N.; Nishikawa, K.; Shirasawa S.; Uchida, M.; Aoki, S.; Wada, K. Recombinant human 5-HT5A receptors stably expressed in C6 glioma cells couple to multiple signal transduction pathways. J. Neurochem., 2003, 84, 222-232.
25. Wilson, H. L.; Dipp, M.; Thomas, J. T.; Lad, C.; Galione, A.; Evans, A. M. ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase act as redox sensors. J. Biol. Chem., 2001, 276, 1180-1188.
26. +-glycohydrolase in brain from CD38-deficient mice. J. Biol. Chem., 2003, 278, 40670-40678.
27. +: a novel role for CD38. Biochem. Biophys. Res. Commun., 2006, 10, 1016.
28. +: a novel potential pharmacological target for metabolic conditions. Curr. Pharm. Des., 2009, 15, 57-63.
29. Tang B. L.; Chua C. E. L. SIRT1 and neuronal diseases. Mol. Aspects Med. 2008, 29, 187-200.
30. Cohem D. E.; Supinski A. M.; Bonkowski M. S.; Donmez G.; Guarente L. P. Neuronal SIRT1 regulates endocrine and behavioral responses to calorie restriction. Genes Devel., 2009, 23, 2812-2817.
31. Michan, S.; Li, Y.; Chou, M. M-H.; Parrella, E.; Ge, H.; Long, J. M.; Allard, J. S.; Lewis, K.; Miller, M.; Xu, W.; Mervis, R. F.; Chen, J.; Guerin, K. I.; Smith, L. E.; McBurney, M. W.; Sinclair, D. A.; Baudry, M.; de Cabo, R.; Longo, V. D. SIRT1 is essential for normal cognitive function and synaptic plasticity. J. Neurosci., 2010, 30, 9695-9707.
32. Aksoy, P.; Escande, C.; White, T. A.; Thompson, M.; Soares, S.; Benech, J. C.; Chini, E. N. Regulation of SIRT 1 mediated NAD dependent deacetylation: a novel role for the multifunctional enzyme CD38. Biochem. Biophys. Res. Commun., 2006, 349, 353-359.
33. + oscillation. Aging, 2011, 3, 1-9.
34. +: an old metabolite controlling new metabolic signaling pathways. Endocrine Reviews, 2010, 31, 194-223.
35. 2+ elevation by synthetic carbocyclic analogs of cyclic ADP-ribose and their antagonistic effects in NG108-15 neuronal cells. J. Neurochem., 2005, 94, 316-323.
36. 2+ mobilization in dopamine neurons. J. Neurosci., 2003, 23, 149-157.
37. Chung, K. K.; Freestone, P. S.; Lipski, J. Expression and functional properties of TRPM2 channels in dopaminergic neurons of the substantianigra of the rat. J. Neurophysiol., 2011, 106, 2865-2875.
38. Toth, B.; Csanady L. Identification of direct and indirect effectors of the transient receptor potential melastatin 2 (TRPM2) cation channel. J. Biol. Chem., 2010, 285, 30091-30102.
39. Massullo, P.; Sumoza-Toledo, A.; Bhagat, H.; Partida-Sanchez, S. TRPM channels, calcium and redox sensors during innate immune responses. Seminars Cell Devel. Biol., 2006, 17, 654-666.
40. Higashida, H.; Lopatina, O.; Yoshihara, T.; Pichugina, Y. A.; Soumarokov, A. A.; Munesue, T.; Minabe, Y.; Kikuchi, M.; Ono, Y.; Korshunova, N.; Salmina, A. B. Oxytocin signal and social behaviour: comparison among adult and infant oxytocin, oxytocin receptor and CD38 gene knockout mice. J. Neuroendocrinol., 2010, 22, 373-379.
41. Lu, H.; Burns, D.; Garnier, P.; Wei, G.; Zhu, K.; Ying, W. P2X7 receptors mediate NADH transport across the plasma membrane of astrocytes. Biochem. Biophys. Res. Comm., 2007, 362, 946-950.
42. Bruzzone, S.; Basile, G.; Chothi, M. P.; Nobbio, L.; Usai, C.; Jacchetti, E.; Schenone, A.; Guse A. H; Di Virgilio, F.; De Flora, A.; Zocchi, E. Diadenosinehomodinucleotide products of ADP-ribosyl cyclases behave as modulators of the purinergic receptor P2X7. J. Biol. Chem., 2010, 285, 21165-21174.
43. +-consuming ectoenzymes in the endocrine system. J. Mol. Endocrinol., 2010, 45, 183-191.
44. Xu, X. J.; Boumechache, M.; Robinson, L. E.; Marschall, V.; Gorecki, D. C.; Masin, M.; Murrell-Lagnado, R. D. Splice variants of the P2X7 receptor reveal differential agonist dependence and functional coupling with pannexin-1. J. Cell Sci., 2012, 125, 3776-3789.
45. Sandilos, J. K.; Bayliss, D. A. Physiological mechanisms for the modulation of pannexin 1 channel activity. J. Physiol., 2012, 590, 6257-6266.
46. Bennett, M. V.; Garré, J. M.; Orellana, J. A.; Bukauskas, F. F.; Nedergaard, M.; Sáez, J. C. Connexin and pannexin hemichannels in inflammatory responses of glia and neurons. Brain Res., 2012, 1487, 3-15.
47. Naviaux, R. K.; Zolkipli, Z.; Wang, L.; Nakayama, T.; Naviaux, J. C.; Le, T. P.; Schuchbauer, M. A.; Rogac, M.; Tang, Q.; Dugan, L. L.; Powell, S. B. Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model. PLoS One, 2013, 8, e57380.
48. Heinrichs, M.; Domes, G. Neuropeptides and social behaviour: effects of oxytocin and vasopressin in humans. Prog. Brain. Res., 2008, 170, 337-350.
49. Ebstein, R. P.; Israel, S.; Lerer, E.; Uzefovsky, F.; Shalev, I.; Gritsenko, I.; Riebold, M.; Salomon, S.; Yirmiya, N. Arginine vasopressin and oxytocin modulate human social behavior. Ann. N. Y. Acad. Sci., 2009, 1167, 87-102.
50. Veenema, A. H; Neumann, I. D. Central vasopressin and oxytocin release: regulation of complex social behaviours. Prog. Brain Res., 2008, 170, 261-276.
51. Viero, C.; Shibuya, I.; Kitamura, N.; Verkhratsky, A.; Fujihara, H.; Katoh, A.; Ueta, Y.; Zingg H. H.; Chvatal, A.; Sykova, E.; Dayanithi, G. Oxytocin: Crossing the bridge between basic science and pharmacotherapy. CNS Neurosci. Ther., 2010, 16, e138-56.
52. Bosch, O. J.; Meddle, S. L.; Beiderbeck, D. I.; Douglas, A. J.; Neumann, I. D. Brain oxytocin correlates with maternal aggression: link to anxiety. J. Neurosci., 2005, 25, 6807-6815.
53. Herzmann, G.; Young, B.; Bird, C. W.; Curran, T. Oxytocin can impair memory for social and non-social visual objects: a withinsubject investigation of oxytocin's effects on human memory. Brain Res., 2012, 1451, 65-73.
54. Neumann, I. D. Brain oxytocin: a key regulator of emotional and social behaviours in both females and males. J. Neuroendocrinol., 2008, 20, 858-865.
55. Marazziti, D.; Roncaglia, I.; Del Debbio, A.; Bianchi, C.; Massimetti, G.; Origlia, N.; Domenici, L.; Piccinni, A.; Dell'Osso, L. Brain-derived neurotrophic factor in romantic attachment. Psychol. Med., 2009, 39, 1927-1930.
56. Strathearn, L.; Fonagy, P.; Amico, J.; Montague, P. R. Adult attachment predicts maternal brain and oxytocin response to infant cues. Neuropsychopharmacology, 2009, 34, 2655-2666.
57. Kret, M. E.; De Dreu, C. K. Oxytocin-motivated ally selection is moderated by fetal testosterone exposure and empathic concern. Front. Neurosci., 2013, 7, 1.
58. Dai, L.; Carter, C. S.; Ying, J.; Bellugi, U.; Pournajafi-Nazarloo, H.; Korenberg, J. R. Oxytocin and vasopressin are dysregulated in Williams Syndrome, a genetic disorder affecting social behavior. PLoS One., 2012, 7, e38513.
59. Lucas, M.; Frenois, F.; Cador, M.; Le Moine, C. Remodeling of the neuronal circuits underlying opiate-withdrawal memories following remote retrieval. Neurobiol. Learn. Mem., 2012, 97, 47-53.
60. Scheele, D.; Striepens, N.; Güntürkün, O.; Deutschländer, S.; Maier, W.; Kendrick, K. M.; Hurlemann, R. Oxytocin modulates social distance between males and females. J. Neurosci., 2012, 32, 16074-16079.
61. Neumann, I. D.; Landgraf, R. Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors. Trends Neurosci., 2012, 35, 649-659.
62. Atzil, S.; Hendler, T.; Zagoory-Sharon, O.; Winetraub, Y.; Feldman, R. Synchrony and specificity in the maternal and the paternal brain: relations to oxytocin and vasopressin. J. Am. Acad. Child. Adolesc. Psychiat., 2012, 51, 798-811.
63. Zheng. J.; Babygirija, R.; Bülbül, M.; Cerjak, D.; Ludwig, K.; Takahashi, T. Hypothalamic oxytocin mediates adaptation mechanism against chronic stress in rats. Am. J. Physiol. Gastrointest. Liver Physiol., 2010, 299, G946-G953.
64. Pournajafi-Nazarloo, H.; Kenkel, W.; Mohsenpour, S. R.; Sanzenbacher, L.; Saadat, H.; Partoo, L.; Yee, J.; Azizi, F.; Carter, C. S. Exposure to chronic isolation modulates receptors mRNAs for oxytocin and vasopressin in the hypothalamus and heart. Peptides, 2013, 43C, 20-26.
65. Windle, R. J.; Gamble, L. E.; Kershaw, Y. M.; Wood, S. A.; Lightman, S. L.; Ingram, C. D. Gonadal steroid modulation of stressinduced hypothalamo-pituitary-adrenal activity and anxiety behavior: role of central oxytocin. Endocrinology, 2006, 147, 2423-2431.
66. Miller, M.; Bales, K. L.; Taylor, S. L.; Yoon, J.; Hostetler, C. M.; Carter, C. S.; Solomon, M. Oxytocin and vasopressin in children and adolescents with autism spectrum disorders: sex differences and associations with symptoms. Autism Res., 2013, 6, 91-102.
67. Shughrue, P. J.; Dellovade, T. L.; Merchenthaler, I. Estrogen modulates oxytocin gene expression in regions of the rat supraoptic and paraventricular nuclei that contain estrogen receptor-beta. Prog. Brain Res., 2002, 139, 15-29.
68. Dayanithi, G.; Viero, C.; Shibuya, I. The role of calcium in the action and release of vasopressin and oxytocin from CNS neurones/terminals to the heart. J. Physiol. Pharmacol., 2008, 59, 7-26.
69. Knott, T. K.; Hussy, N.; Cuadra, A. E.; Lee, R. H.; Ortiz-Miranda, S.; Custer, E. E.; Lemos, J. R. Adenosine trisphosphate appears to act via different receptors in terminals versus somata of the hypothalamic neurohypophysial system. J. Neuroendocrinol., 2012, 24, 681-689.
70. Widmer, H.; Ludwig, M.; Bancel, F.; Leng, G.; Dayanithi, G. Neurosteroid regulation of oxytocin and vasopressin release from the rat supraoptic nucleus. J. Physiol., 2003, 548, 233-244.
71. 2+ influx. J. Neurosci., 2004, 24, 1226-1235.
72. Leng, G.; Meddle, S. L.; Douglas, A. J. Oxytocin and the maternal brain. Curr. Opin. Pharmacol., 2008, 8, 731-734.
73. Dayanithi, G.; Forostyak, O.; Ueta, Y.; Verkhratsky, A.; Toescu, E. C. Segregation of calcium signalling mechanisms in magnocellularneurones and terminals. Cell Calcium, 2012, 51, 293-299.
74. Tobin, V.; Leng, G.; Ludwig, M. The involvement of actin, calcium channels and exocytosis proteins in somato-dendritic oxytocin and vasopressin release. Front. Physiol., 2012, 3, 261.
75. Tobin, V. A.; Ludwig, M. The actin filament and dendritic peptide release. Biochem. Soc. Trans., 2007, 35, 1243-1246.
76. Lemos, J. R.; Ortiz-Miranda, S. I.; Cuadra, A. E.; Velázquez-Marrero, C.; Custer, E. E.; Dad, T.; Dayanithi, G. Modulation/physiology of calcium channel sub-types in neurosecretory terminals. Cell Calcium, 2012, 51, 284-292.
77. Modahl, C.; Green, L.; Fein, D.; Morris, M.; Waterhouse, L.; Feinstein, C.; Levin, H. Plasma oxytocin levels in autistic children. Biol. Psychiatry, 1998, 43, 270-277.
78. Hollander, E.; Novotny, S.; Hanratty, M.; Yaffe, R.; DeCaria, C. M.; Aronowitz, B. R.; Mosovich, S. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology, 2003, 28, 193-198.
79. Guastella, A. J.; Howard, A. L.; Dadds, M. R.; Mitchell, P.; Carson, D. S. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology, 2009, 34, 917-923.
80. Hollander, E.; Bartz, J.; Chaplin, W,.; Phillips, A.; Sumner, J.; Soorya, L.; Anagnostou, E.; Wasserman, S. Oxytocin increases retention of social cognition in autism. Biol. Psychiatry, 2007, 61, 498-503.
81. Gurrieri, F.; Neri, G. Defective oxytocin function: a clue to understanding the cause of autism? BMC Med., 2009, 7, 63.
82. Israel, S.; Lerer, E.; Shalev, I.; Uzefovsky, F.; Reibold, M.; Bachner-Melman, R.; Granot, R.; Bornstein, G.; Knafo, A.; Yirmiya, N.; Ebstein, R. P. Molecular genetic studies of the arginine vasopressin 1a receptor (AVPR1a) and the oxytocin receptor (OXTR) in human behaviour: from autism to altruism with some notes in between. Prog. Brain Res., 2008, 170, 435-449.
83. Gregory, S. G.; Connelly, J. J.; Towers, A. J.; Johnson, J.; Biscocho, D.; Markunas, C. A.; Lintas, C.; Abramson, R. K.; Wright, H. H.; Ellis, P.; Langford, C. F.; Worley, G.; Delong, G. R.; Murphy, S. K.; Cuccaro, M. L.; Persico, A.; Pericak-Vance, M. A. Genomic and epigenetic evidence for oxytocin receptor deficiency in autism. BMC Med., 2009, 7, 62.
84. Munesue, T.; Yokoyama, S.; Nakamura, K.; Anitha, A.; Yamada, K.; Hayashi, K.; Asaka, T.; Liu, H. X.; Jin, D.; Koizumi, K.; Islam, M. S.; Huang, J. J.; Ma, W. J.; Kim, U. H.; Kim, S. J.; Park, K.; Kim, D.; Kikuchi, M.; Ono, Y.; Nakatani, H.; Suda, S.; Miyachi, T.; Hirai, H.; Salmina, A.; Pichugina, Y. A.; Soumarokov, A. A; Takei, N.; Mori, N.; Tsujii, M.; Sugiyama, T.; Yagi, K.; Yamagishi, M.; Sasaki, T.; Yamasue, H.; Kato, N.; Hashimoto, R.; Taniike, M.; Hayashi, Y.; Hamada, J.; Suzuki, S.; Ooi, A.; Noda, M.; Kamiyama, Y.; Kido, M. A.; Lopatina, O.; Hashii, M.; Amina, S.; Malavasi, F.; Huang, E. J.; Zhang, J.; Shimizu, N.; Yoshikawa, T.; Matsushima, A.; Minabe, Y.; Higashida, H. Two genetic variants of CD38 in subjects with autism spectrum disorder and controls. Neurosci. Res., 2010, 67, 181-191.
85. Jin, D.; Liu, H. X.; Hirai, H.; Torashima, T.; Nagai, T.; Lopatina, O.; Shnayder, N. A.; Yamada, K.; Noda, M.; Seike, T.; Fujita, K.; Takasawa, S.; Yokoyama, S.; Koizumi, K.; Shiraishi, Y.; Tanaka, S.; Hashii, M.; Yoshihara, T.; Higashida, K.; Islam, M. S.; Yamada, N.; Hayashi, K.; Noguchi, N.; Kato, I.; Okamoto, H.; Matsushima, A.; Salmina, A.; Munesue, T.; Shimizu, N.; Mochida, S.; Asano, M.; Higashida, H. CD38 is critical for social behaviour by regulating oxytocin secretion. Nature, 2007, 446, 41-45.
86. Liu, H. X.; Lopatina, O.; Higashida, C.; Tsuji, T.; Kato, I.; Takasawa, S.; Okamoto, H.; Yokoyama, S.; Higashida, H. Locomotor activity, ultrasonic vocalization and oxytocin levels in infant CD38 knockout mice. Neurosci. Lett., 2008, 448, 67-70.
87. 2+ concentrations is involved in autoregulation of oxytocin secretion in the hypothalamus and posterior pituitary in male mice. Neuropharmacology, 2010, 58, 50-55.
88. Higashida, H.; Yokoyama, S.; Munesue, T.; Kikuchi, M.; Minabe, Y.; Lopatina, O. CD38 gene knockout juvenile mice: a model of oxytocin signal defects in autism. Biol. Pharm. Bull., 2011, 34, 1369-1372.
89. Mangas, A.; Bodet, D.; Duleu, S.; Yajeya, J.; Geffard, M.; Coveñas, R. Direct visualization of retinoic acid in the rat hypothalamus: an immunohistochemical study. Neurosci. Lett., 2012, 509, 64-68.
90. Stoney, P.; Morgan, P.; McCaffery, P. Retinoic acid regulates growth-related gene expression in the rat hypothalamus. Endocrine Abstracts, 2012, 29, 1111.
91. i, and insulin secretion. J. Biol. Chem., 1999, 274, 1869-1872.
92. + metabolites and single nucleotide polymorphisms of CD38. Neurochem. Int., 2012, 61, 828-838.
93. Lopatina, O.; Inzhutova, A.; Salmina, A. B.; Higashida, H. The roles of oxytocin and CD38 in social or parental behaviors. Front. Neurosci., 2012, 6, 182.
94. Liu, H. X.; Lopatina, O.; Higashida, C.; Fujimoto, H.; Akther, S.; Inzhutova, A.; Liang, M.; Zhong, J.; Tsuji, T.; Yoshihara, T.; Sumi, K.; Ishiyama, M.; Ma, W. J.; Ozaki, M.; Yagitani, S.; Yokoyama, S.; Mukaida, N.; Sakurai, T.; Hori, O.; Yoshioka, K.; Hirao, A.; Kato, Y.; Ishihara, K.; Kato, I.; Okamoto, H.; Cherepanov, S. M.; Salmina, A. B.; Hirai, H.; Asano, M.; Brown, D. A.; Nagano, I.; Higashida, H. Displays of paternal mouse pup retrieval following communicative interaction with maternal mates. Nat. Commun., 2013, 4, 1346.
95. Feldman, R.; Zagoory-Sharon, O.; Weisman, O.; Schneiderman, I.; Gordon, I.; Maoz, R; Shalev, I.; Ebstein, R. P. Sensitive parenting is associated with plasma oxytocin and polymorphisms in the OXTR and CD38 genes. Biol. Psychiatry., 2012, 72, 175-181.
96. Andari, E.; Duhamel, J. R.; Zalla, T.; Herbrecht, E.; Leboyer, M., Sirigu, A. Promotingsocial behavior with oxytocin in high-functioning autism spectrum disorders. Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 4389-4394.
97. Huffmeijer, R.; Alink, L. R.; Tops, M.; Grewen, K. M.; Light, K. C.; Bakermans-Kranenburg, M. J., Ijzendoorn, M. H. Salivary levels of oxytocin remain elevated for more than two hours after intranasal oxytocin administration. NeuroEndocrinol. Lett., 2012, 33, 21-25.
98. Takase, K.; Oda, S.; Kuroda, M.; Funato, H. Monoaminergic and neuropeptidergic neurons have distinct expression profiles of histone deacetylases. PLoS One, 2013, 8, e58473.
99. Bethlehem, R. A.; van Honk, J.; Auyeung, B.; Baron-Cohen S. Oxytocin, brain physiology, and functional connectivity: A review of intranasal oxytocin fMRI studies. Psychoneuroendocrinology, 2012, 38, 962-974.
100. Yamasue, H. Function and structure in social brain regions can link oxytocin-receptor genes with autistic social behavior. Brain Dev., 2013, 35, 111-118.
101. Liberzon, I.; Chalmers, D. T.; Mansour, A.; Lopez, J. F.; Watson, S. J.; Young, E. A. Glucocorticoid regulation of hippocampal oxytocin receptor binding. Brain Res., 1994, 650, 317-322.
102. Cohen, H.; Kaplan, Z.; Kozlovsky, N.; Gidron, Y.; Matar, M. A.; Zohar, J. Hippocampal microinfusion of oxytocin attenuates the behavioural response to stress by means of dynamic interplay with the glucocorticoid-catecholamine responses. J. Neuroendocrinol., 2010, 22, 889-904.
103. Neumann, I. D.; Wigger, A.; Liebsch, G.; Holsboer, F.; Landgraf, R. Increased basal activity of the hypothalamo-pituitary-adrenal axis during pregnancy in rats bred for high anxiety-related behaviour. Psychoneuroendocrinology, 1998, 23, 449-463.
104. Ferguson, J. N.; Aldag, J. M.; Insel, T. R.; Young, L. J. Oxytocin in the medial amygdale is essential for social recognition in the mouse. J. Neurosci., 2001, 21, 8278-8285.
105. Hurlemann, R.; Patin, A.; Onur, O. A.; Cohen, M. X.; Baumgartner, T.; Metzler, S., Dziobek, I.; Gallinat, J.; Wagner, M.; Maier, W.; Kendrick, K. M. Oxytocin enhances amygdala-dependent, socially reinforced learning and emotional empathy in humans. J. Neurosci., 2010, 30, 4999-5007.
106. Landgraf, R.; Neumann, I. D. Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. Front. Neuroendocrinol., 2004, 25, 150-176.
107. Neumann, I. D. Stimuli and consequences of dendritic release of oxytocin within the brain. Biochem. Soc. Trans., 2007, 35, 1252-1257.
108. Knobloch, H. S.; Charlet, A.; Hoffmann, L. C.; Eliava, M.; Khrulev, S.; Cetin, A. H.; Osten, P.; Schwarz, M. K.; Seeburg, P. H.; Stoop, R.; Grinevich, V. Evoked axonal oxytocin release in the central amygdala attenuates fear response. Neuron, 2012, 73, 553-566.
109. Higashida, H.; Munesue, T.; Yokoyama, S.; Hashii, M.; Koizumi, K.; Matsushima, A. A missense mutation in CD38 associated with autism spectrum disorder in three pedigrees. In: Autism-A Neurodevelopmental Journey from Genes to Behaviour; Dr. Valsamma Eapen, (Ed.); In Tech: 2011; pp. 183-196.
110. GeneCards database. Transient receptor potential cation channel, subfamily M, member 2. http://www. genecards. org/cgibin/carddisp. pl?gene=TRPM2 (Accessed April 7, 2013).
111. Huber, D.; Veinante, P.; Stoop, R. Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. Science, 2005, 308, 245-248.
112. Blouin, A. M.; Fried, I.; Wilson, C. L.; Staba, R. J.; Behnke, E. J.; Lam, H. A.; Maidment, N. T.; Karlsson, K. A.; Lapierre, J. L.; Siegel, J. M. Human hypocretin and melanin-concentrating hormone levels are linked to emotion and social interaction. Nat. Commun., 2013, 4, 1547.
113. Andari, E.; Schneider, F. C.; Mottolese, R.; Vindras, P.; Sirigu, A. Oxytocin's fingerprint in personality traits and regional brain volume. Cereb. Cortex., 2012. Nov 1. [Epub ahead of print] doi: 10. 1093/cercor/bhs328.
114. Petrovic, P.; Kalisch, R.; Singer, T.; Dolan, R. J. Oxytocin attenuates affective evaluations of conditioned faces and amygdala activity. J. Neurosci., 2008, 28, 6607-6615.
115. Wang, Y.; He, Z.; Zhao, C.; Li, L. Medial amygdala lesions modify aggressive behavior and immediate early gene expression in oxytocin and vasopressin neurons during intermale exposure. Behav. Brain Res., 2013, 245, 42-49.
116. Choleris, E.; Little, S. R.; Mong, J. A.; Puram, S. V.; Langer, R.; Pfaff, D. W. Microparticle-based delivery of oxytocin receptor antisense DNA in the medial amygdala blocks social recognition in female mice. Proc. Natl. Acad. Sci. U S A., 2007, 104, 4670-4675.
117. Rosenfeld, A. J.; Lieberman, J. A.; Jarskog, L. F. Oxytocin, dopamine, and the amygdala: a neurofunctional model of social cognitive deficits in schizophrenia. Schizophr. Bull., 2011, 37, 1077-1087.
118. Domes, G.; Heinrichs, M.; Michel, A.; Berger, C.; Herpertz, S. C. Oxytocin improves "mind-reading" in humans. Biol. Psychiat., 2007, 61, 731-733.
119. Gamer, M. Does the amygdala mediate oxytocin effects on socially reinforced learning? J. Neurosci., 2010, 30, 9347-9348.
120. Ebner, K.; Bosch, O. J.; Krömer, S. A.; Singewald, N.; Neumann, I. D. Release of oxytocin in the rat central amygdala modulates stress-coping behavior and the release of excitatory amino acids. Neuropsychopharmacology, 2005, 30, 223-230.
121. Furman, D. J.; Chen, M. C.; Gotlib, I. H. Variant in oxytocin receptor gene is associated with amygdala volume. Psychoneuroendocrinology, 2011, 36, 891-897.
122. Arakawa, H.; Arakawa, K.; Deak, T. Oxytocin and vasopressin in the medial amygdala differentially modulate approach and avoidance behavior toward illness-related social odor. Neuroscience, 2010, 171, 1141-1151.
123. Crawley, J. N. Translational animal models of autism and neurodevelopmental disorders. Dialogues Clin. Neurosci., 2012, 14, 293-305.
124. Stavropoulos, K. K.; Carver, L. J. Research review: Social motivation and oxytocin in autism-implications for joint attention development and intervention. J. Child Psychol. Psychiatry., 2013, 54, 603-618.
125. Bale, T. L.; Baram, T. Z.; Brown, A. S.; Goldstein, J. M.; Insel, T. R.; McCarthy, M. M.; Nemeroff, C. B.; Reyes, T. M.; Simerly, R. B.; Susser, E. S.; Nestler, E. J. Early life programming and neurodevelopmental disorders. Biol. Psychiat., 2010, 68, 314-319.
126. Zocchi, L.; Sassone-Corsi, P. SIRT1-mediated deacetylation of MeCP2 contributes to BDNF expression. Epigenetics, 2012, 7, 695-700.
127. Ullah, N.; Lee, H. Y.; Naseer, M. I.; Ullah, I.; Suh, J. W.; Kim, M. O. Nicotinamide inhibits alkylating agent-induced apoptotic neurodegeneration in the developing rat brain. PLoS One, 2011, 6, e27093.
128. Ceni, C.; Pochon, N.; Brun, V.; Muller-Steffner, H.; Andrieux, A.,; Grunwald, D.; Schuber, F.; De Waard, M.; Lund, F.; Villaz, M.; Moutin, M. J. CD38-dependent ADP-ribosyl cyclase in developing and adult mouse brain. Biochem. J., 2003, 370, 175-183.
129. Salmina, A. B. Neuron-glia interactions as therapeutic targets in neurodegeneration. J. Alzheimers Dis., 2009, 16, 485-502.
130. Carter, C. S.; Boone, E. M.; Pournajafi-Nazarloo, H.; Bales, K. L. Consequences of early experiences and exposure to oxytocin and vasopressin are sexually dimorphic. Dev. Neurosci., 2009, 31, 332-341.
131. Rankin, S. L.; Partlow, G. D; McCurdy, R. D.; Giles, E. D; Fisher, K. R. Postnatal neurogenesis in the vasopressin and oxytocincontaining nucleus of the pig hypothalamus. Brain Res., 2003, 97, 189-196.
132. Raymond, A. D.; Kucherepa, N. N.; Fisher, K. R.; Halina, W. G.; Partlow, G. D. Neurogenesis of oxytocin-containing neurons in the paraventricular nucleus (PVN) of the female pig in 3 reproductive states: puberty gilts, adult gilts and lactating sows. Brain Res., 2006, 1102, 44-51.
133. Bertsch, K.; Schmidinger, I.; Neumann, I. D; Herpertz, S. C. Reduced plasma oxytocin levels in female patients with borderline personality disorder. Horm. Behav., 2013, 63, 424-429.
134. Lieberwirth, C.; Wang, Z. The social environment and neurogenesis in the adult Mammalian brain. Front. Hum. Neurosci., 2012, 6, 118.
135. Lévy, F.; Gheusi, G.; Keller, M. Plasticity of the parental brain: a case for neurogenesis. J. Neuroendocrinol., 2011, 23, 984-993.
136. Mak, G. K.; Weiss, S. Paternal recognition of adult offspring mediated by newly generated CNS neurons. Nat. Neurosci., 2010, 13, 753-758.
137. Feierstein, C. E.; Lazarini, F.; Wagner, S.; Gabellec, M. M.; de Chaumont, F.; Olivo-Marin, J. C.; Boussin, F. D.; Lledo, P. M.; Gheusi, G. Disruption of adult neurogenesis in the olfactory bulb affects social interaction but not maternal behavior. Front. Behav. Neurosci., 2010, 4, 176.
138. Feierstein, C. E. Linking adult olfactory neurogenesis to social behavior. Front. Neurosci., 2012, 6, 173.
139. Musaelyan, K.; Anacker, C.; Zunszain, P. A.; Pariante, C. M. The effects of oxytocin on hippocampal neurogenesis. In: Neural Development & Plasticity Abstracts, Proceedings of The Physiological Society, Poster Communications, King's College London, UK, 2011, Proc. Physiol. Soc. 22, PC27.
140. Leuner, B.; Caponiti, J. M.; Gould, E. Oxytocin stimulates adult neurogenesis even under conditions of stress and elevated glucocorticoids. Hippocampus, 2012, 22, 861-868.
141. Bakos, J.; Strbak, V.; Paulikova, H.; Krajnakova, L.; Lestanova, Z.; Bacova, Z. Oxytocin receptor ligands induce changes in cytoskeleton in neuroblastoma cells. J. Mol. Neurosci., 2013, 50, 462-468.
142. Bales, K. L.; Boone, E.; Epperson, P.; Hoffman, G.; Carter, C. S. Are behavioral effects of early experience mediated by oxytocin? Front. Psychiatry, 2011, 2, 24.
143. Murgatroyd, C. A.; Nephew, B. C. Effects of early life social stress on maternal behavior and neuroendocrinology. Psychoneuroendocrinology, 2013, 38, 219-228.
144. Bales, K. L.; Lewis-Reese, A. D.; Pfeifer, L. A.; Kramer, K. M.; Carter, C. S. Early experience affects the traits of monogamy in a sexually dimorphic manner. Dev. Psychobiol., 2007, 49, 335-342.
145. Bales, K. L.; Plotsky, P. M.; Young, L. J.; Lim, M. M.; Grotte, N.; Ferrer, E.; Carter, C. S. Neonatal oxytocin manipulations have longlasting, sexually dimorphic effects on vasopressin receptors. Neuroscience, 2007, 144, 38-45.
146. Oreland, S.; Gustafsson-Ericson, L.; Nylander, I. Short-and longterm consequences of different early environmental conditions on central immunoreactive oxytocin and arginine vasopressin levels in male rats. Neuropeptides, 2010, 44, 391-398.
147. Branchi, I.; Curley, J. P.; D'Andrea, I.; Cirulli, F.; Champagne, F. A.; Alleva, E. Early interactions with mother and peers independently build adult social skills and shape BDNF and oxytocin receptor brain levels. Psychoneuroendocrinology, 2013, 38, 522-532.
148. Riem, M. M.; van Ijzendoorn, M. H.; Tops, M.; Boksem, M. A.; Rombouts, S. A.; Bakermans-Kranenburg, M. J. Oxytocin effects on complex brain networks are moderated by experiences of maternal love withdrawal. Eur. Neuropsychopharmacol., 2013, 23, 1288-1295.
149. Feldman, R.; Gordon, I.; Influs, M.; Gutbir, T.; Ebstein, R. P. Parental oxytocin and early caregiving jointly shape children's oxytocin response and social reciprocity. Neuropsychopharmacology, 2013, 38, 1154-1162.
150. Huffmeijer, R.; van Ijzendoorn, M. H.; Bakermans-Kranenburg, M. J. Ageing and oxytocin: a call for extending human oxytocin research to ageing populations-a mini-review. Gerontology, 2013, 59, 32-39.
151. Domes, G.; Heinrichs, M.; Kumbier, E.; Grossmann, A.; Hauenstein, K.; Herpertz, S. C. Effects of intranasal oxytocin on the neural basis of face processing in autism spectrum disorder. Biol. Psychiat., 2013, 74, 164-171.
152. Macdonald, K.; Feifel, D. Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders. Front. Neurosci., 2013, 7, 35.
153. Rault, J. L.; Carte, C. S.; Garner, J. P.; Marchant-Forde, J. N.; Richert, B. T.; Lay, D. C. Jr. Repeated intranasal oxytocin administration in early life dysregulates the HPA axis and alters social behavior. Physiol. Behav. 2013, 112-113C, 40-48.
154. Hirosawa, T.; Kikuchi, M.; Higashida, H.; Okumura, E.; Ueno, S.; Shitamichi, K.; Yoshimura, Y.; Munesue, T.; Tsubokawa, T.; Haruta, Y.; Nakatani, H.; Hashimoto, T.; Minabe, Y. Oxytocin attenuates feelings of hostility depending on emotional context and individuals' characteristics. Sci. Rep., 2012, 2, 384.
155. Bartz, J. A.; Zaki, J.; Ochsner, K. N.; Bolger, N.; Kolevzon, A.; Ludwig, N.; Lydon, J. E. Effects of oxytocin on recollections of maternal care and closeness. Proc. Natl. Acad. Sci. U S A., 2010, 107, 21371-21375.
156. Salmina, A. B.; Shul'man, V. A.; Nikulina, S. Y.; Trufanova, L. V.; Fursov, A. A.; But'yanov, P. A.; Kuskaev, A. P.; Bol'shakova, E. V.; Kotlovskii, M. Y. Apoptosis of leukocytes as a marker of neutrophil-endotheliocyte interaction in coronary heart disease. Bull. Exp. Biol. Med., 2007, 144, 39-41.
157. Wagner, G. K.; Black, S.; Guse, A. H.; Potter, B. V. First enzymatic synthesis of an N1-cyclised cADPR (cyclic-ADP ribose) analogue with a hypoxanthine partial structure: discovery of a membrane permeant cADPR agonist. Chem. Commun. (Camb.), 2003, 15, 1944-1945.
158. Gu, X.; Yang, Z.; Zhang, L.; Kunerth, S.; Fliegert, R.; Weber, K.; Guse, A. H.; Zhang, L. Synthesis and biological evaluation of novel membrane-permeant cyclic ADP-ribose mimics: N1-[(5″-Ophosphorylethoxy) methyl]-5′-O-phosphorylinosine 5′, 5″-cyclicpyrophosphate (cIDPRE) and 8-substituted derivatives. J. Med. Chem., 2004, 47, 5674-5682.
159. Lee, H. C.; Munshi, C.; Graeff, R. Structures and activities of cyclic ADP-ribose, NAADP and their metabolic enzymes. Mol. Cell. Biochem., 1999, 193, 89-98.
160. 2+-mobilizing second messenger cyclic ADP-ribose. J. Am. Chem. Soc., 2001, 123, 8750-8759.
161. 2+-mobilizing second messenger. Structure-activity relationship of the N1-ribose moiety. J. Am. Chem. Soc., 2005, 127, 8846-8855.
162. Sauve, A. A.; Schramm, V. L. Mechanism-based inhibitors of CD38: a mammalian cyclic ADP-ribose synthetase. Biochemistry, 2002, 41, 8455-8463.
163. + glycohydrolase activity of CD38 by carbocyclic NAD analogues. Biochem. J., 1998, 335, 631-636.
164. Kim, U. H. Kidney ADP-ribosyl cyclase inhibitors as a therapeutic tool for diabetic nephropathy, In: Diabetic nephropathy, Dr. John Chan (Ed.); InTech, 2012; pp. 85-96.
165. Kwong, A. K.; Chen, Z.; Zhang, H.; Leung, F. P.; Lam, C. M.; Ting, K. Y.; Zhang, L.; Hao, Q.; Zhang, L. H.; Lee, H. C. Catalysis-based inhibitors of the calcium signaling function of CD38. Biochemistry, 2012, 51, 555-564.
166. Kellenberger, E.; Kuhn, I.; Schuber, F.; Muller-Steffner, H. Flavonoids as inhibitors of human CD38. Bioorg. Med. Chem. Lett., 2011, 21, 3939-3942.
167. Zhao, Y. J.; Zhang, H. M.; Lam, C. M.; Hao, Q.; Lee, H. C. Cytosolic CD38 protein forms intact disulfides and is active in elevating intracellular cyclic ADP-ribose. J. Biol. Chem., 2011, 286, 22170-22177.
168. Dong, M.; Si, Y. Q.; Sun, S. Y.; Pu, X. P.; Yang, Z. J.; Zhang, L. R.; Zhang, L. H.; Leung, F. P.; Lam, C. M.; Kwong, A. K.; Yue, J.; Zhou, Y.; Kriksunov, I. A.; Hao, Q.; Lee, H. C. Design, synthesis and biological characterization of novel inhibitors of CD38. Org. Biomol. Chem., 2011, 9, 3246-3257.
169. Mehta K. Retinoid-Mediated Signaling and CD38 Expression. In: Cyclic ADP-Ribose and NAADP; Lee H. C. (Ed.) Springer US, 2002; pp 409-425.
170. Riebold, M.; Mankuta, D.; Lerer, E.; Israel, S.; Zhong, S.; Nemanov, L.; Monakhov, M. V.; Levi, S.; Yirmiya, N.; Yaari, M.; Malavasi, F.; Ebstein, R. P. All-trans retinoic acid upregulates reduced CD38 transcription in lymphoblastoid cell lines from Autism spectrum disorder. Mol. Med., 2011, 17, 799-806.
171. Ebstein, R. P.; Mankuta, D.; Yirmiya, N.; Malavasi, F. Are retinoids potential therapeutic agents in disorders of social cognition including autism? FEBS Lett., 2011, 585, 1529-1536.
172. Vilboux, T.; Ciccone, C.; Blancato, J. K.; Cox, G. F.; Deshpande, C.; Introne, W. J.; Gahl, W. A.; Smith, A. C.; Huizing, M. Molecular analysis of the Retinoic Acid Induced 1 gene (RAI1) in patients with suspected Smith-Magenis syndrome without the 17p11. 2 deletion. PLoS One, 2011, 6, e22861.
173. Girirajan, S.; Elsea, S. H. Abnormal maternal behavior, altered sociability, and impaired serotonin metabolism in Rai1-transgenic mice. Mamm. Genome, 2009, 20, 247-255.
174. Carmona-Mora, P.; Walz, K. Retinoic Acid Induced 1, RAI1: A dosage sensitive gene related to neurobehavioral alterations including autistic behavior. Curr. Genomics, 2010, 11, 607-617.
175. Cai, L.; Yan, X. B.; Chen, X. N.; Meng, Q. Y.; Zhou, J. N. Chronic all-trans retinoic acid administration induced hyperactivity of HPA axis and behavioral changes in young rats. Eur. Neuropsychopharmacol., 2010, 20, 839-847.
176. Shearer, K. D.; Fragoso, Y. D.; Clagett-Dame, M.; McCaffery, P. J. Astrocytes as a regulated source of retinoic acid for the brain. Glia, 2012, 60, 1964-1976.
177. Matsuzaki, M.; Matsushita, H.; Tomizawa, K.; Matsui, H. Oxytocin: a therapeutic target for mental disorders. J. Physiol. Sci., 2012, 62, 441-444.
178. Salmina, A. B.; Okuneva, O. S.; Mikhutkina, S. V.; Malinovskaya, N. A.; Morgun, A. V.; Zykova, L. D.; Yudin, G. V.; Laletin, D. V.; Fursov, M. A.; Frolova, O. V.; Tagaeva, G. A.; Bolshakova, E. V. Perinatal hypoxic-ischemic brain injury affects the glutamatergic signal transduction coupled with neuronal ADP-ribosyl cyclase activity. Bull. Exp. Bio. l Med., 2011, 150, 583-586.
179. Kou, W.; Banerjee, S.; Eudy, J.; Smith, L. M.; Persidsky, R.; Borgmann, K.; Wu, L.; Sakhuja, N.; Deshpande, M. S.; Walseth, T. F.; Ghorpade, A. CD38 regulation in activated astrocytes: implications for neuroinflammation and HIV-1 brain infection. J. Neurosci. Res., 2009, 87, 2326-2339.
180. Choe, C. U.; Lardong, K.; Gelderblom, M.; Ludewig, P.; Leypoldt, F.; Koch-Nolte, F.; Gerloff, C.; Magnus, T. CD38 exacerbates focal cytokine production, postischemic inflammation and brain injury after focal cerebral ischemia. PLoS On., 2011, 6, e19046.
181. Higashida, H.; Yokoyama, S.; Kikuchi, M.; Munesue, T. CD38 and its role in oxytocin secretion and social behavior. Horm. Behav., 2012, 61, 351-358.
182. Higashida, H. Biological basis for social recognition: CD38 controls oxytocin secretion. Tanpakushitsu Kakusan Koso., 2007, 52, 1832-1839.